Antibody-drug conjugate against ALK could selectively treat neuroblastoma

Researchers from CHOP and Celldex showed that an antibody-drug conjugate targeting ALK selectively kills neuroblastoma cells, suggesting the ADC could have a better safety profile than marketed drug dinutuximab.

Unituxin dinutuximab from United Therapeutics Corp. (NASDAQ:UTHR) and Qarziba dinutuximab beta from EUSA Pharma Ltd. (Hemel Hempstead, U.K.) are approved to treat pediatric patients with high-risk neuroblastoma. However, these anti-GD2 mAbs can lead to side effects including anaphylaxis and neurotoxicity, with relapse occurring in half of patients...